Biomedicines 2014, 2(1), 36-49; doi:10.3390/biomedicines2010036
Review

Oncolytic Adenoviruses in Cancer Treatment

1 Catalan Institute of Oncology (ICO), Av. Gran Via s/n km 2,7, Hospitalet de Llobregat, Barcelona 08907, Spain 2 Biomedical Research Institute of Bellvitge (IDIBELL), 3a planta - Gran Via de l'Hospitalet, 199, Hospitalet de Llobregat, Barcelona 08907, SpainĀ 
Received: 15 January 2014; in revised form: 13 February 2014 / Accepted: 14 February 2014 / Published: 21 February 2014
(This article belongs to the Special Issue Gene Therapy Used in Cancer Treatment)
PDF Full-text Download PDF Full-Text [310 KB, uploaded 21 February 2014 10:37 CET]
Abstract: The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic administration. Limited efficacy has been associated to poor tumor targeting, intratumoral spread, and virocentric immune responses. A deeper understanding of these three barriers will be required to design more effective oncolytic adenoviruses that, alone or combined with chemotherapy or immunotherapy, may become tools for oncologists.
Keywords: oncolytic; adenovirus; virotherapy; cancer

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Alemany, R. Oncolytic Adenoviruses in Cancer Treatment. Biomedicines 2014, 2, 36-49.

AMA Style

Alemany R. Oncolytic Adenoviruses in Cancer Treatment. Biomedicines. 2014; 2(1):36-49.

Chicago/Turabian Style

Alemany, Ramon. 2014. "Oncolytic Adenoviruses in Cancer Treatment." Biomedicines 2, no. 1: 36-49.

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert